Safety and Treatment Effectiveness of a Single Autologous Protein Solution Injection in Patients with Knee Osteoarthritis.
Osteoarthritis (OA) is a common degenerative condition characterized by pain and loss of function. A pathological biochemical environment with excess inflammatory and catabolic proteins is a major contributor to OA. nSTRIDE(®) Autologous Protein Solution (APS) is a new therapy under development for the treatment of OA. This therapy is formed from a patient's blood and contains high concentrations of anti-inflammatory and anabolic proteins. This study assessed the safety and treatment effects of APS. Eleven subjects with early to moderate OA were injected with APS. Subjects were closely monitored for adverse events (AE) following the injection. Treatment outcome measures were obtained before injection. AE and clinical outcomes were assessed at 1 and 2 weeks postinjection and 1, 3, and 6 months postinjection. There were no serious AE or AE that were reported by the investigator as greater than mild in severity. There were no AE that were related to the device. There were minor AE related to the injection procedure, including injection site discomfort (1/11), injection site joint pain (1/11), and procedural nausea (1/11), which resolved quickly and did not require treatment. Mean Western Ontario and McMaster Universities Arthritis Index (WOMAC) composite scores and pain, stiffness, and function subscale scores all showed significant improvement compared to baseline by 2 weeks postinjection. The data presented here suggest that the treatment is safe and show a complication profile that is mild and consistent with similar treatments. A single injection of APS for treatment of early to moderate knee OA led to symptom improvement over the study course. Based on these results, an adequately powered, well-controlled, randomized multicenter study to establish clinical efficacy is warranted.
Department of Orthopedic Surgery, St. Anna Hospital , Geldrop, The Netherlands .
Rogier A M
RA
van Drumpt
Department of Orthopedic Surgery, St. Anna Hospital , Geldrop, The Netherlands .
Walter
W
van der Weegen
Zimmer Biomet , Warsaw, Indiana.
William
W
King
Zimmer Biomet , Warsaw, Indiana.
Krista
K
Toler
Zimmer Biomet , Warsaw, Indiana.
Mitchell M
MM
Macenski
APS; IL-1; IRAP; TNFα; pain; platelet-rich plasma
Ann Rheum Dis. 2010 Sep;69(9):1580-8
20699241
Radiology. 2009 Sep;252(3):647-61
19717750
Inflamm Res. 2011 Oct;60(10):929-36
21687998
Am J Sports Med. 2011 Oct;39(10):2135-40
21846925
Osteoarthritis Cartilage. 2013 Jan;21(1):10-5
23041436
Am J Sports Med. 2014 May;42(5):1204-10
24634448
J Rheumatol. 2003 Jul;30(7):1648-54
12858473
Instr Course Lect. 1998;47:487-504
9571450
J Exp Orthop. 2016 Dec;3(1):9
26915009
Am J Phys Med Rehabil. 2012 May;91(5):411-7
22513879
BMC Musculoskelet Disord. 2012 Nov 23;13:229
23176112
Osteoarthritis Cartilage. 2004 May;12(5):389-99
15094138
J Orthop Res. 2014 Oct;32(10):1349-55
24981198
Plast Reconstr Surg. 2004 Nov;114(6):1502-8
15509939
J Knee Surg. 2015 Feb;28(1):3-10
25068847
Ann Rheum Dis. 2009 Dec;68(12 ):1890-3
19054828
J Rheumatol. 2015 Mar;42(3):363-71
25593231
Knee Surg Sports Traumatol Arthrosc. 2012 Oct;20(10):2082-91
22203046
Biomaterials. 2007 Nov;28(31):4551-60
17659771
Am J Vet Res. 2014 Feb;75(2):141-51
24471750
Nat Rev Rheumatol. 2014 Jan;10(1):11-22
24189839
Am J Phys Med Rehabil. 2010 Dec;89(12 ):961-9
21403592
Drug Saf. 2000 Aug;23(2):115-30
10945374
J Orthop Res. 2013 Dec;31(12):1929-35
23966313
J Orthop Res. 2011 Sep;29(9):1320-6
21437966
BMC Musculoskelet Disord. 2015 Jun 20;16:153
26092588
Knee Surg Sports Traumatol Arthrosc. 2011 Apr;19(4):528-35
20740273